

Docket No.  
1874/110

# NEW UTILITY PATENT APPLICATION TRANSMITTAL

## (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission  
87**TO THE ASSISTANT COMMISSIONER FOR PATENTS**
**Box Patent Application**  
**Washington, D.C. 20231**

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

Methods for Modulating Hematopoiesis and Vasculogenesis

and invented by:

 Margaret H. Baron  
 Sarah M. Farrington  
 Maria Belaoussoff

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

 Continuation    Divisional    Continuation-in-part (CIP)   of prior application No.: \_\_\_\_\_

Enclosed are:

**Application Elements**

1.  Filing fee as calculated and transmitted as described below
2.  Specification having 57 pages and including the following:
  - a.  Descriptive Title of the Invention
  - b.  Cross References to Related Applications (*if applicable*)
  - c.  Statement Regarding Federally-sponsored Research/Development (*if applicable*)
  - d.  Reference to Microfiche Appendix (*if applicable*)
  - e.  Background of the Invention
  - f.  Brief Summary of the Invention
  - g.  Brief Description of the Drawings (*if drawings filed*)
  - h.  Detailed Description
  - i.  Claim(s) as Classified Below
  - j.  Abstract of the Disclosure
3.  Drawing(s) (*when necessary as prescribed by 35 USC 113*)
  - a.  Formal
  - b.  Informal

Number of Sheets 21

# NEW UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
1874/110

Total Pages in this Submission  
87

## Application Elements (Continued)

4.  Oath or Declaration
  - a.  Newly executed (*original or copy*)  Unexecuted
  - b.  Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)
  - c.  With Power of Attorney  Without Power of Attorney
5.  Incorporation By Reference (*usable if Box 4b is checked*)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6.  Computer Program in Microfiche
7.  Genetic Sequence Submission (*if applicable, all must be included*)
  - a.  Paper Copy
  - b.  Computer Readable Copy
  - c.  Statement Verifying Identical Paper and Computer Readable Copy

## Accompanying Application Parts

8.  Assignment Papers (*cover sheet & documents*)
9.  37 CFR(B) Statement (*when there is an assignee*)
10.  English Translation Document (*if applicable*)
11.  Information Disclosure Statement/PTO-1449  Copies of IDS Citations
12.  Preliminary Amendment
13.  Acknowledgment postcard
14.  Certificate of Mailing
  - First Class  Express Mail (*Specify Label No.:* EMS29205313US)
15.  Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
16.  Small Entity Statement(s) - Specify Number of Statements Submitted: \_\_\_\_\_


# NEW UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
1874/110

Total Pages in this Submission  
87

## Accompanying Application Parts (Continued)

17.  Additional Enclosures (please identify below):  
  


## Fee Calculation and Transmittal

### CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	56	- 20 =	36	x \$11.00	\$396.00
Indep. Claims	7	- 3 =	4	x \$41.00	\$164.00
Multiple Dependent Claims (check if applicable)	<input type="checkbox"/>				\$0.00
				BASIC FEE	\$395.00
OTHER FEE (specify purpose)					
				TOTAL FILING FEE	\$955.00

A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.


Charge the amount of \_\_\_\_\_ as filing fee.

Credit any overpayment.

Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: February 10, 1998



Signature

Harriet M. Strimpel, D. Phil.  
Registration No. 37,008  
BROMBERG & SUNSTEIN LLP  
125 Summer Street  
Boston, MA 02110  
(617) 443-9292

cc:

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Baron et al.

Docket No.


1874/110

Serial No.  
Not Yet AssignedFiling Date  
HerewithExaminer  
Not Yet AssignedGroup Art Unit  
Not Yet Assigned

Invention: Methods for Modulating Hematopoiesis and Vascular Growth

I hereby certify that this New Utility Patent Application Transmittal and enclosures referred to therein  
*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  
February 10, 1998  
*(Date)*

Jorge D. Betancourt*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)*EM529205313US*("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.